title: [Individual changes of gene expression in the interferon system in human blood cells due to amixin and cycloferon].
abstract: The action of amixin and cycloferon on the expression of genes in the systems of interferon (IF) and cell apoptosis (CA) was studied by semi-quantitative RT-PCR in human blood microsamples before and after the administration of the drugs. Individual changes were determined in the transcription activity of genes of IF (alpha, beta, gamma), enzymes 2',5' oligoadenylatesynthetase (OAS), RNSase L, dsRNA-dependent proteinkinase (dsPK) and of CA effectors (FasAg, bcl-2, gamma-actin) registered dynamically in 24 h and 48 h. The activity parameters of IF genes were compared with the results of biological titration of IF activity in blood samples in vivo and in vitro. A pronounced ability of cycloferon to stimulate selectively the activity of genes of human IF, type I (beta IF--by 100 times and alpha IF--by 10 times), without affecting essentially the activity of other genes in blood cells, was detected. Amixin was found to inhibit the titration of genes with high activity levels. (alpha-, beta-IF, RNAases L, bcl-2 and gamma-actin). The antiviral and IF-induced properties of the drug are explained to a great extent by the apoptotic effect (activation of genes Fas, gamma-IF, OAS and affected transcription of gene bcl-2). A positive correlation was observed between the processes of activation of IF-genes transcription and the production of the total circulating IF. Antagonistic relations between type I and II IFs in human blood cells were shown.
authors.forename: T M
authors.initials: TM
authors.lastname: Sokolova
authors.forename: L V
authors.initials: LV
authors.lastname: Uryvaev
authors.forename: E B
authors.initials: EB
authors.lastname: Tazulakhova
authors.forename: F I
authors.initials: FI
authors.lastname: Ershov
authors.forename: I K
authors.initials: IK
authors.lastname: Malyshenkova
authors.forename: N A
authors.initials: NA
authors.lastname: Didkovskiĭ
mesh_terms: D000166:Acridines / Q000008:administration & dosage / Q000494:pharmacology*; D000284:Administration, Oral; D000998:Antiviral Agents / Q000008:administration & dosage / Q000494:pharmacology*; D017209:Apoptosis; D001773:Blood Cells / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects*; D006801:Humans; D066298:In Vitro Techniques; D007273:Injections, Intramuscular; D007369:Interferon Inducers / Q000008:administration & dosage / Q000494:pharmacology*; D016898:Interferon-alpha / Q000097:blood / Q000235:genetics*; D016899:Interferon-beta / Q000097:blood / Q000235:genetics*; D007371:Interferon-gamma / Q000097:blood / Q000235:genetics*; D008875:Middle Aged; D012333:RNA, Messenger / Q000032:analysis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013994:Tilorone / Q000008:administration & dosage / Q000494:pharmacology*; D014158:Transcription, Genetic / Q000187:drug effects
chemical_list: D000166:Acridines; D000998:Antiviral Agents; D007369:Interferon Inducers; D016898:Interferon-alpha; D012333:RNA, Messenger; D016899:Interferon-beta; D007371:Interferon-gamma; D013994:Tilorone; C026430:10-carboxymethyl-9-acridanone